1 – 10 of 36
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease : clinical and therapeutic considerations
(
- Contribution to journal › Scientific review
-
Mark
Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
(
- Contribution to journal › Scientific review
-
Mark
Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia
(
- Contribution to journal › Article
- 2022
-
Mark
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain : rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
(
- Contribution to journal › Article
- 2020
-
Mark
Basal ganglia oscillations as biomarkers for targeting circuit dysfunction in Parkinson's disease
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The role of glia in Parkinson's disease : Emerging concepts and therapeutic applications
(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2018
-
Mark
Levodopa effect and motor function in late stage Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Dopaminergic effect on non-motor symptoms in late stage Parkinson's disease
(
- Contribution to journal › Article
- 2017
-
Mark
Device-Aided Treatment Strategies in Advanced Parkinson's Disease
(
- Contribution to journal › Article
- 2016
-
Mark
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease : An open-label prospective observational study of effectiveness, tolerability and healthcare costs
(
- Contribution to journal › Article